[PRESS RELEASE] – TORONTO, Jan. 13, 2026 – MediPharm Labs Corp., a pharmaceutical company specializing in precision-based cannabinoids, announced the signing of a definitive supply agreement with Remidose Aerosols Inc. for the shipment of GMP-certified medicinal cannabis products to Costa Rica.
“MediPharm Labs’ proven ability to navigate complex regulatory environments enables us to deliver GMP-certified cannabinoid products to highly regulated markets worldwide,” MediPharm Labs CEO David Pidduck said. “This agreement strengthens our commitment to supporting medical patients in Costa Rica and advancing international access to quality cannabis solutions.”
Costa Rica’s medical cannabis market officially opened to regulated sales in June 2025 and is projected to exceed $35 million annually, driven by strong patient demand and a comprehensive regulatory framework focused on product safety and GMP compliance.1
Under the agreement, MediPharm Labs will supply a range of GMP-certified cannabis products, including oils, tinctures, metered dose inhalers and dried flower to Remidose’s affiliated entity, Remidose LATAM SRL. Remidose LATAM has already advanced its regulatory process, and shipment will begin once the remaining requirements are completed.
“Remidose LATAM is proud to be fully licensed and authorized by Costa Rican health authorities to import medicinal cannabis products,” Remidose President Michael Mayne said. “Partnering with MediPharm Labs allows us to offer patients access to some of the highest-quality, GMP-certified cannabis products available globally. MediPharm’s standards, reliability and proven ability to deliver in regulated markets make them the ideal partner for our mission to improve patient care in Costa Rica.”
1 Costa Rica Medical Cannabis Market (2025-2031) – 6Wresearch, April 2025. https://www.6wresearch.com/industry-report/costa-rica-medical-cannabis-market
